Nrf2 regulators
US-10604509-B2 · Mar 31, 2020 · US
NRF2 activators
US11028099B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11028099-B2 |
| Application number | US-201716469203-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 11, 2017 |
| Priority date | Dec 15, 2016 |
| Publication date | Jun 8, 2021 |
| Grant date | Jun 8, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid: or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable excipients.
Assignees
Inventors
Classifications
of the kidneys · CPC title
Antineoplastic agents · CPC title
- C07D498/04Primary
Ortho-condensed systems · CPC title
Drugs for disorders of the cardiovascular system · CPC title
ortho- or peri-condensed with heterocyclic ring systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11028099B2 cover?
- The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator.
- Who is the assignee on this patent?
- Glaxosmithkline Ip Dev Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D498/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).